Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies
By Don Nico Forbes
Shares in Zentalis Pharmaceuticals rose after the company said the U.S. Food and Drug Administration lifted a partial clinical halt on studies of its cancer treatment azenosertib.
Shares were up 41% in premarket trading at $4.57.
The company said Monday that the regulator cleared the drug's enrollment in all continuing clinical studies, with no changes to its clinical development plan.
Azenosertib is an orally-ingested inhibitor of WEE1--a protein linked with various forms of cancer--currently being tested in monotherapy and combination clinical studies for ovarian cancer and additional tumor types.
Zentalis said it remains on track to meet all previously-disclosed data guidance for 2024, and that it will present data for azenosertib as a monotherapy later this year.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
September 16, 2024 07:52 ET (11:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks